Skip to main content

Table 5 Relationship between patient satisfaction and disease- and treatment-related information received

From: Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain

  n   Effectiveness Adverse events Cost Convenience
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Before starting the treatment, did your doctor speak to you about the disease?
 Yes, at length 112 76.34 (17.6) 69.91 (36.35) 40.0 (25.86) 86.74 (13.10) 79.63 (15.12)
 Yes, a little 14 62.50 (17.84) 77.86 (31.85) 33.2 (25.91) 82.50 (8.03) 72.14 (15.65)
 p value1)   0.002 0.446 0.272 0.050 0.108
Did your doctor speak to you about the different possible treatments for your disease?
 Yes, at length 100 76.70 (17.56) 70.40 (36.57) 40.45 (26.45) 87.70 (12.50) 78.85 (15.73)
 Yes, a little 25 69.40 (17.52) 68.80 (36.15) 35.20 (23.07) 80.00 (11.99) 77.72 (16.20)
 p value1   0.012 0.959 0.577 0.007 0.491
Did your doctor speak to you about the characteristics of GRAZAX®?
 Yes, at length 105 76.33 (18.00) 68.62 (37.65) 39.38 (26.47) 87.57 (12.39) 78.84 (15.95)
 Yes, a little 20 69.50 (15.30) 77.75 (28.07) 39.50 (22.59) 78.75 (12.23) 77.50 (15.09)
 p value1   0.023 0.904 0.460 0.008 0.237
  1. 1The p value was calculated using the bilateral ANOVA parametric test (or nonparametric Kruskal–Wallis) with a 95% confidence level